Inventiva (NASDAQ:IVA) Shares Gap Down – Time to Sell?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares gapped down prior to trading on Wednesday . The stock had previously closed at $4.56, but opened at $4.27. Inventiva shares last traded at $4.5040, with a volume of 487,692 shares trading hands.

Analysts Set New Price Targets

Several research firms have issued reports on IVA. Truist Financial assumed coverage on Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Finally, Wall Street Zen lowered shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Inventiva currently has a consensus rating of “Buy” and an average price target of $16.56.

Inventiva Stock Performance

The firm’s 50-day moving average price is $4.46 and its 200 day moving average price is $5.32.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Paradigm Biocapital Advisors LP acquired a new stake in shares of Inventiva during the 4th quarter valued at approximately $18,600,000. ADAR1 Capital Management LLC bought a new stake in Inventiva during the fourth quarter valued at $12,601,000. Millennium Management LLC increased its stake in Inventiva by 2,267.7% during the fourth quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after purchasing an additional 2,540,540 shares during the last quarter. UBS Group AG raised its holdings in shares of Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after purchasing an additional 2,634,580 shares during the period. Finally, SymBiosis Capital Partners LLC acquired a new stake in shares of Inventiva during the fourth quarter worth $12,090,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.